SCHEMBL1004738

SCHEMBL1004738

CCOC(=O)c1nocc1C1CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.40
KDM4E B2RXH2 5/20 0.37
MAPT P10636 4/20 0.37
MEN1 O00255 3/20 0.37
LMNA P02545 3/20 0.37
KMT2A Q03164 3/20 0.37
TSHR P16473 2/20 0.37
HSD17B10 Q99714 2/20 0.37
USP2 O75604 1/20 0.37
TARBP2 Q15633 1/20 0.37
TP53 P04637 1/20 0.37
ALOX12 P18054 1/20 0.37
CACNA1F O60840 1/20 0.37
CACNA1D Q01668 1/20 0.37
CACNA1S Q13698 1/20 0.37
CACNA1C Q13936 1/20 0.37
HTT P42858 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ELANE P08246 2/20 0.36
ALDH1A1 P00352 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23293575 0.79 PTGDR2 (0.34) ALDH1A1
SCHEMBL21523633 0.79 HPGD (0.35) HPGDKDM4EMAPTMEN1LMNA
SCHEMBL6873803 0.77 HPGD (0.43) HPGDKDM4EMAPTLMNAKMT2A
SCHEMBL31296900 0.76 LMNA (0.50) HPGDKDM4EMAPTMEN1LMNA
SCHEMBL934890 0.76 TSHR (0.42) KDM4EMAPTMEN1LMNAKMT2A
SCHEMBL8920076 0.76 CA12 (0.46) HPGDKDM4ELMNATARBP2HTT
SCHEMBL1704374 0.75 HCAR2 (0.36) MAPT
SCHEMBL18490196 0.74 PDE4B (0.38) HPGDKDM4ETSHRTP53NPSR1
SCHEMBL22727456 0.74 TARBP2 (0.44) HPGDKDM4EMAPTKMT2ATSHR
SCHEMBL26921830 0.74 HTT (0.46) HPGDKDM4EMAPTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025024521-A1 SUBSTITUTED PIPERIDINEDIONES FOR TARGETED PROTEIN DEGRADATION MONTE ROSA THERAPEUTICS, INC. (US) 2025-01-30 WO disclosed
EP-4408530-A1 BENZIMIDAZOLES AS MODULATORS OF IL-17 Janssen Pharmaceutica NV (BE) 2024-08-07 EP disclosed
CN-118119613-A Benzimidazoles as IL-17 modulators 詹森药业有限公司 2024-05-31 CN disclosed
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 US disclosed
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 US disclosed
US-11691979-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
US-11691979-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
WO-2023049888-A1 BENZIMIDAZOLES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-03-30 WO disclosed
EP-4143195-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 Janssen Pharmaceutica NV (BE) 2023-03-08 EP disclosed
US-20220402922-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN RESEARCH & DEVELOPMENT, LLC 2022-12-22 US disclosed
WO-2021222404-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN BIOTECH, INC. (US) 2021-11-04 WO disclosed
EP-2456308-A2 PYRIDINE DERIVATIVES FOR CONTROLLING INVERTREBATE PESTS BASF SE (DE) 2012-05-30 EP disclosed
WO-2011009804-A2 PYRIDINE DERIVATIVES COMPOUNDS FOR CONTROLLING INVERTEBRATE PESTS BASF SE (DE) 2011-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11691979-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 HPGD 567/4885KDM4E 2583/4885MAPT 3647/4885
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 HPGD 567/4885KDM4E 2583/4885MAPT 3647/4885
US-20220402922-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 HPGD 567/4885KDM4E 2583/4885MAPT 3647/4885
US-11702422-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 HPGD 567/4885KDM4E 2583/4885MAPT 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.